Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...

JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zai Lab (ZLAB – Research Report), Perspective ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), with a price ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Zai Lab (NASDAQ:ZLAB) Ltd on Thursday, setting a price target ...

Taking on Gary Trent Jr., Shai Gilgeous-Alexander drove left before he spun right and scored on a fadeaway short mid-range ...